KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Debt to Equity (2020 - 2025)

Supernus Pharmaceuticals has reported Debt to Equity over the past 9 years, most recently at $0.03 for Q4 2025.

  • Quarterly Debt to Equity fell 36.01% to $0.03 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $0.03 through Dec 2025, down 36.01% year-over-year, with the annual reading at $0.03 for FY2025, 36.01% down from the prior year.
  • Debt to Equity was $0.03 for Q4 2025 at Supernus Pharmaceuticals, up from $0.01 in the prior quarter.
  • Over five years, Debt to Equity peaked at $0.52 in Q4 2021 and troughed at $0.01 in Q3 2025.
  • The 5-year median for Debt to Equity is $0.05 (2024), against an average of $0.09.
  • The largest YoY upside for Debt to Equity was 1518.63% in 2022 against a maximum downside of 95.42% in 2022.
  • A 5-year view of Debt to Equity shows it stood at $0.52 in 2021, then crashed by 95.42% to $0.02 in 2022, then skyrocketed by 137.1% to $0.06 in 2023, then decreased by 19.11% to $0.05 in 2024, then tumbled by 36.01% to $0.03 in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Debt to Equity are $0.03 (Q4 2025), $0.01 (Q3 2025), and $0.03 (Q1 2025).